glp 1 indication Researchers find GLP-1 medications safe to continue before surgery in patients with diabetes and obesity GLP-1 Drug Overdose

The cardiovascular risk reduction in high-risk diabetic and obese patients is large

GLP-1 agonists are part of a long-term treatment plan

Key risk factors contributing to this increase were obesity and a family history of diabetes, both of which were more prevalent among younger individuals

Key Points Animal studies suggest that endogenous, central glucagon-like peptide 1 (GLP-1) regulates both short-term and long-term energy balance, potentially via activation of hindbrain and hypothalamic GLP-1 receptors (GLP1R), respectively Endogenous peripheral GLP-1 may limit meal size by activation of GLP1R on local vagal afferent nerves and stimulation of a gutbrain feedback loop Increasing GLP1R activity by administering GLP-1 receptor agonists reduces food intake and promotes weight loss in humans, but the extent to which endogenous GLP-1 regulates energy balance in humans remains unknown Although diabetes mellitus and obesity appear to be associated with altered GLP-1 system activity, GLP1R agonists retain their efficacy in these contexts, making them a viable therapeutic tool A better understanding of how endogenous central and peripheral GLP-1 regulate energy balance has the potential to maximize our application of GLP-1-based therapies for the treatment of obesity This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access $189.00 per year only $15.75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF

The Final Verdict While the idea of weight loss patches may seem appealing, they fall short of delivering the transformative results of GLP-1 injections

The problem is that this system can become dysregulated